Global Clinical Whole Exome Sequencing (WES) Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical
Publisher : MRA | Format : PDF
Global Clinical Whole Exome Sequencing (WES) Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Clinical Whole Exome Sequencing (WES) is a comprehensive genetic test that identifies changes in a patient's DNA that cause or are related to their medical problems. By focusing on the entire protein-coding region of the genome (the exome), it provides the coverage needed to diagnose patients quickly and reliably.
Global Clinical Whole Exome Sequencing (WES) market is projected to reach US$ million in 2033, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2033. Demand from Rare Genetic Disease and Genetic Testing Unsuccessful are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Clinical Whole Exome Sequencing (WES) industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2023 to 2033.
Globally, Clinical Whole Exome Sequencing (WES) key companies include CentoXome, Mayo Clinic Laboratories, Baylor Genetics, Blueprint Genetics, GeneDx, CD Genomics, Illumina, Thermo Fisher and Labassure, etc. CentoXome, Mayo Clinic Laboratories, Baylor Genetics are top 3 players and held % share in total in 2022.
Clinical Whole Exome Sequencing (WES) can be divided into Array-Based Exome Enrichment and Enrichment of the Exome in Solution using Biotinylated Probes, etc. Array-Based Exome Enrichment is the mainstream product in the market, accounting for % share globally in 2022.
Clinical Whole Exome Sequencing (WES) is widely used in various fields, such as Rare Genetic Disease, Genetic Testing Unsuccessful and Others,, etc. Rare Genetic Disease provides greatest supports to the Clinical Whole Exome Sequencing (WES) industry development. In 2022, global % share of Clinical Whole Exome Sequencing (WES) went into Rare Genetic Disease filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Clinical Whole Exome Sequencing (WES) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
CentoXome
Mayo Clinic Laboratories
Baylor Genetics
Blueprint Genetics
GeneDx
CD Genomics
Illumina
Thermo Fisher
Labassure
Yale Medicine
Genosalut
Caris Life Sciences
InterGenetics
Genomics and Pathology Services (GPS)
3billion
Broad Genomic
Roche
Novogene
BGI Genomics
Shanghai Jingzhou Genomics
Shihe Gene Biotechnology
JUNO Genomics
Segment by Type
Array-Based Exome Enrichment
Enrichment of the Exome in Solution using Biotinylated Probes
Rare Genetic Disease
Genetic Testing Unsuccessful
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Clinical Whole Exome Sequencing (WES) market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2033).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Clinical Whole Exome Sequencing (WES) introduction, etc. Clinical Whole Exome Sequencing (WES) Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12MRAResearch’s Conclusions of Clinical Whole Exome Sequencing (WES) market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by MRAResearch.
Global Clinical Whole Exome Sequencing (WES) market is projected to reach US$ million in 2033, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2033. Demand from Rare Genetic Disease and Genetic Testing Unsuccessful are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Clinical Whole Exome Sequencing (WES) industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2023 to 2033.
Globally, Clinical Whole Exome Sequencing (WES) key companies include CentoXome, Mayo Clinic Laboratories, Baylor Genetics, Blueprint Genetics, GeneDx, CD Genomics, Illumina, Thermo Fisher and Labassure, etc. CentoXome, Mayo Clinic Laboratories, Baylor Genetics are top 3 players and held % share in total in 2022.
Clinical Whole Exome Sequencing (WES) can be divided into Array-Based Exome Enrichment and Enrichment of the Exome in Solution using Biotinylated Probes, etc. Array-Based Exome Enrichment is the mainstream product in the market, accounting for % share globally in 2022.
Clinical Whole Exome Sequencing (WES) is widely used in various fields, such as Rare Genetic Disease, Genetic Testing Unsuccessful and Others,, etc. Rare Genetic Disease provides greatest supports to the Clinical Whole Exome Sequencing (WES) industry development. In 2022, global % share of Clinical Whole Exome Sequencing (WES) went into Rare Genetic Disease filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Clinical Whole Exome Sequencing (WES) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
By Company
CentoXome
Mayo Clinic Laboratories
Baylor Genetics
Blueprint Genetics
GeneDx
CD Genomics
Illumina
Thermo Fisher
Labassure
Yale Medicine
Genosalut
Caris Life Sciences
InterGenetics
Genomics and Pathology Services (GPS)
3billion
Broad Genomic
Roche
Novogene
BGI Genomics
Shanghai Jingzhou Genomics
Shihe Gene Biotechnology
JUNO Genomics
Segment by Type
Array-Based Exome Enrichment
Enrichment of the Exome in Solution using Biotinylated Probes
Segment by Application
Rare Genetic Disease
Genetic Testing Unsuccessful
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Clinical Whole Exome Sequencing (WES) market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2033).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Clinical Whole Exome Sequencing (WES) introduction, etc. Clinical Whole Exome Sequencing (WES) Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12MRAResearch’s Conclusions of Clinical Whole Exome Sequencing (WES) market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by MRAResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices